Sarborg announced that the patent was developed using its proprietary Signature Agent and Multi-Agent platform, supported by its Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database. According to Sarborg, this approach enables rapid identification of new therapeutic opportunities, including additional indications and combination strategies, with patent filing achieved in less than three weeks.

CDT believes this development represents a strong validation of Sarborg's platform capabilities and its ability to systematically generate high-value intellectual property within compressed timeframes. As a 20% shareholder in Sarborg, CDT views this as a significant step in demonstrating the commercial potential of agentic, data-driven pharmaceutical development.

CDT is working with Sarborg to evaluate its existing asset portfolio in the context of these capabilities, including the identification of potential combination therapies involving CDT's assets and the compounds covered by Sarborg's recently filed patent. The Company intends to leverage this approach to expand its intellectual property position and unlock additional commercial opportunities.